Skip to main content
. Author manuscript; available in PMC: 2013 Jan 1.
Published in final edited form as: Drug Discov Today. 2011 Sep 18;17(1-2):71–80. doi: 10.1016/j.drudis.2011.09.009

Figure 3.

Figure 3

Improved therapeutic effects of curcumin by curcumin conjugate (PCurc8) formulation in cancer cells. (a) Cytotoxicity effect of PCurc 8 formulation in SKOV-3, OVCAR-3 and MCF-7 cancer cell lines after 72-h incubation followed by 24-h incubation in free medium. (b) Intracellular localization of curcumin conjugate observed by confocal microscopy. SKOV-3 ovarian cancer cells incubated with PCurc 8 at 25 µg/ml for 2 h (i–iii) and 24 h (iv–vi). PCurc 8 channel (green, left column) and the LysoTracker® channel (red, middle column), and overlapped channels (right column). (vi) also indicates the overlap of the nuclear dye channel with a blue color. (c) Immunoblotting with anti-cyclin D1, CDK4, CDK6 and procaspase-3 antibodies after treating cells with 10, 20 and 40 µg/ml of PCurc 8. Downregulation of CDK4 and CDK6 indicates that the SKOV-3 cells were hindered at the G0/G1 or G1 phases before going into S phase. Reprinted, with permission, from [47].